Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02684058 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
NCT02684058 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 151 participants.
The verdict
NCT02684058, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
Study Summary
The purpose of this study was to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma (LGG) or relapsed or refractory high grade glioma (HGG)
Interventions
- DRUG Carboplatin
- DRUG Vincristine
- DRUG trametinib
- DRUG Dabrafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2017-12-28 |
| Est. Completion | 2023-04-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02684058
The ClinicalTrials.gov registry entry for NCT02684058 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT02684058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02684058 about?
NCT02684058 is a clinical study titled "Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors". The purpose of this study was to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma (LGG) or relapsed or refractory high grade glioma (HGG)
What is the current status of trial NCT02684058?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2017-12-28. Estimated completion is 2023-04-28.
What interventions are being tested in trial NCT02684058?
The interventions under investigation include: Carboplatin (DRUG), Vincristine (DRUG), trametinib (DRUG), Dabrafenib (DRUG).
Who is sponsoring clinical trial NCT02684058?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.